Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-FOLFOXIRI vs A-FOLFOX/FOLFIRI in Right-sided mCRC
NCT03641976Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Jan 2019
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, fluorouracil, folinic acid, oxaliplatin and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colon cancer (2 arms), sponsored by Yonsei University. Primary endpoint: 6-month Progression Free Survival rate. Status: unknown.
02
Drugs
bevacizumabfluorouracilfolinic acidoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT03641976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641976.